{"entity":{"id":"paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","kind":"paper","name":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","aka":["inMIND","Sehn 2026"],"tldr":"Adding a third antibody, directed at a different target, to the usual tablet-and-antibody pairing added about eight months before follicular lymphoma progressed again.","summary":"A phase 3, double-blind, randomised, placebo-controlled trial at 210 centres in North America, Europe and the Asia-Pacific region. Adults with relapsed or refractory follicular lymphoma after at least one previous line were randomised 1 to 1 to up to twelve 28-day cycles of tafasitamab 12 mg per kilogram intravenously, or placebo, both with lenalidomide 20 mg daily on days 1 to 21 of cycles 1 to 12 and rituximab 375 mg per square metre. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population.\n\nBetween 16 April 2021 and 10 August 2023, 548 of 817 patients assessed were enrolled and randomised, 273 to tafasitamab and 275 to placebo; 299 (55 per cent) were male and 249 (45 per cent) female. Median progression-free survival by investigator was 22.4 months (95 per cent confidence interval 19.2 to not evaluable) with tafasitamab against 13.9 months (11.5 to 16.4) with placebo, a hazard ratio of 0.43 (0.32 to 0.58).","asOf":"2026-10-01","links":[{"label":"Lancet 2026","url":"https://doi.org/10.1016/S0140-6736(25)01778-7"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41360064/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/41360064"}],"tags":["lymphoma-evidence"],"related":["lymphoma-roadmap"],"cancers":["follicular-lymphoma","marginal-zone-lymphoma","non-hodgkin-lymphoma"],"sections":["immunotherapy"],"technologies":["monoclonal-antibody"],"targets":["cd19","cd20"],"drugs":["tafasitamab","lenalidomide","rituximab"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04680052"],"people":["laurie-sehn"],"bottlenecks":["b-combination-space","b-resistance"],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"Lancet","year":2026,"doi":"10.1016/S0140-6736(25)01778-7","pmid":"41360064","authors":"Sehn LH, Hübel K, Luminari S, et al.","paperType":"rct","findings":["Median investigator-assessed progression-free survival was 22.4 months with tafasitamab, lenalidomide and rituximab against 13.9 months with placebo, lenalidomide and rituximab (hazard ratio 0.43, 95 per cent confidence interval 0.32 to 0.58).","548 patients were randomised at 210 centres across North America, Europe and the Asia-Pacific region.","The trial was double-blind and placebo-controlled, with patients, investigators and funder masked until the primary analysis.","Eligibility required at least one previous line of systemic therapy, which is a broader population than most relapsed follicular lymphoma trials."],"whatItMeans":"A new combination for relapsed or refractory follicular lymphoma that adds a CD19-directed antibody to the established lenalidomide and rituximab pairing, with the largest progression-free survival hazard ratio reported in the setting.","caveats":["Progression-free survival is the primary endpoint; overall survival data were immature at this analysis.","The comparator, lenalidomide with rituximab, is a reasonable standard, but the trial does not compare against CAR-T or bispecific antibodies, which are the alternatives for early-progressing disease.","Adding a CD19-directed antibody before CAR-T raises a question about subsequent CD19 CAR-T efficacy that the trial does not answer."],"changedPractice":true,"participants":548},"route":"/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/","neighbours":{"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"trial":[{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","route":"/trials/nct04680052/"}],"person":[{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}